These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia. Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599 [TBL] [Abstract][Full Text] [Related]
9. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Corrado ML J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456 [TBL] [Abstract][Full Text] [Related]
11. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Saravolatz LD; Stein GE; Johnson LB Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022 [TBL] [Abstract][Full Text] [Related]
12. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162 [TBL] [Abstract][Full Text] [Related]
13. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462 [TBL] [Abstract][Full Text] [Related]
14. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA; J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566 [TBL] [Abstract][Full Text] [Related]
18. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Garrison MW; Kawamura NM; Wen MM Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512 [TBL] [Abstract][Full Text] [Related]
19. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Steed ME; Rybak MJ Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458 [TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil: drug profile and clinical data. Kanafani ZA Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]